Risk-Based Lung Cancer Detection in COPD Patients
Sponsor: Vejle Hospital • ClinicalTrials.gov ID: NCT07848815
Recruiting for Similar Conditions?
Sponsors are looking for patients like you. See if you qualify for compensated research studies.
Check Eligibility →Description
The goal of the interventional study is to evaluate whether risk-based stratification using the PLCOm2012 model and a machine learning (ML) model can identify patients with chronic obstructive pulmonary disease (COPD) who are at high risk of developing lung cancer and may benefit from low-dose computed tomography (LDCT) screening. The study population includes adults aged 50 years and older with COPD and a history of smoking attending an outpatient clinic. The main question it aims to answer are: \- What is the incidence of histopathologically confirmed lung cancer following risk-based stratification? Participants will: * Undergo lung cancer risk assessment using the PLCOm2012 model and an ML-based model based on clinical and laboratory data * Be referred for LDCT if classified as high-risk * Continue standard care if classified as low-risk * Be followed through electronic health records for up to six years to assess outcomes including lung cancer incidence, adherence to LDCT, time to imaging, healthcare utilization, costs, and safety
Interventions
-
Risk-based prediction models
(Other)
Patients will be stratified into high-risk and low-risk groups using both the Lung Cancer Risk Prediction Calculator for smokers (PLCOm2012) and an in-house developed machine learning model based on sex, age, smoking status, and laboratory data from routine blood sample analyses.
Eligibility criteria
Conditions
Locations
- Vejle Hospital, University Hospital of Southern Denmark — Vejle, Region Syddanmark, Denmark
Partner with Nurenyx
Showcase your study to thousands of motivated patients matching your criteria.
Learn MoreOfficial Source
Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
View Official Record